Cardiac protection by pharmacological modulation of inflammation

Bibliography

• MALLORY GK, WHITE PD, SALCEDO-SALGAR J: The speed of healing of myocardial infarction. A study of the pathologic anatomy in seventy-two cases. Am. Heart J. (1939) 18:647–671.
   Google Scholar
• •Historical interest, as the first to point out to a relation between inflammation and infarction on a pathological basis.
   Google Scholar
• REIMER KA, JENNINGS RB: The `wavefront phenomenon' of myocardial ischemic cell death. Lab. Invest. (1979) 40:633–644.
   PubMed Web of Science ®Google Scholar
• CALIFF RM: Ten years of benefit from aone-hour intervention. Circulation (1994) 98:2649–2651.
   Google Scholar
• MATSUMURA K, JEREMY RW, SCHAPER J, BECKER LC: Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation (1998) 97:795–804.
   PubMed Web of Science ®Google Scholar
• ••First study to clearly prove withsophisticated techniques the existence of reperfusion injury per se.
   Google Scholar
• KLONER RA: Does reperfusion injury exist in humans? j Am. Coll. Cardiol (1993) 21:537–545.
   PubMed Web of Science ®Google Scholar
• ENTMAN ML, SMITH CW: Postreperfusion inflammation: a model forreaction to injury in cardiovascular disease. Cardiovasc. Res. (1994) 28:1301–1311.
   PubMed Web of Science ®Google Scholar
• •In-depth review by authors who have given fundamental contribution in the field of inflammation and cardiovascular disease.
   Google Scholar
• HANSEN PR: Role of neutrophils in myocardial ischemia and reperfusion Circulation (1995) 91:1872–1885.
   Google Scholar
• •Exhaustive and equilibrated review.
   Google Scholar
• BLACK SC: In vivo models of myocardial ischemia and reperfusion injury. Application to drug discovery and evaluation. j Pharmacol Taxied. Meth. (2000) 43:153–167.
   Google Scholar
• •Informative review critically evaluating the relevance of experimental models of UR and the efficacy therapeutic interventions tested.
   Google Scholar
• TOGNONI G: The EMIP project. Eur. Heart J. (2000) 21:1498–1499.
   PubMed Web of Science ®Google Scholar
• ROBERTS R, DEMELLO V, SOBEL BE: Deleterious effects of methylprednisolone in patients with myocardial infarction. Circulation (1976) 53(Suppl. I):204–206.
   Google Scholar
• ROSS R: Atherosclerosis - an inflammatory disease. N Engl. J Med. (1999) 340:115–126.
   PubMed Web of Science ®Google Scholar
• ••Landmark review by an investigator whohas given major contributions to the field.
   Google Scholar
• MANNISI JA, WEISMAN HF, BUSH DE, DUDECK P, HEALY B: Steroid administration after myocardial infarction promotes early infarct expansion. A study in the rat. J Chia. Invest. (1987) 79:1431–1439.
   PubMed Web of Science ®Google Scholar
• •Well conducted experimental study pointing to the relevance of broadening the time window for assessing benefit in experimental MI.
   Google Scholar
• BULKLEY BH, ROBERTS WC. Steroid therapy during acute myocardial infarction: a cause of delayed healing and of ventricular aneurysm. Am. j Med. (1974) 56:244–250.
   PubMed Web of Science ®Google Scholar
• JORDAN JE, ZHAO ZQ, VINTEN-JOHANSEN J: Role of neutrophils in myocardial ischemia-reperfusion injury Cardiovasc. Res. (1999) 43:860–878.
   Google Scholar
• TANHEHCO EJ, LUCCHESI BR: Therapeutic potential of complement inhibitors in myocardial ischaemia. Expert Opirr. Irivestig. Drugs (2000) 9:975–991.
   PubMed Web of Science ®Google Scholar
• •Informative review by a very active group in the field.
   Google Scholar
• ENTMAN ML, YOUKER K, SHAPPEL SB et al: Neutrophil adherence to isolated adult canine myocytes. j Clar. Invest. (1990) 85:1497–1506.
   PubMed Web of Science ®Google Scholar
• KURRELMEYER KM, MICHAEL LH, BAUMGARTEN G etal.: Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemia-induced apoptosis in a murine model of acute myocardial infarction. Proc. Natl. Acad. Sci. USA (2000) 97:5456–5461.
   Google Scholar
• ••First experimental evidence in vivo of aprotective role of TNF early after MI.
   Google Scholar
• FRANCIS GS: TNF-a and heart failure. The difference between proof of principle and hypothesis testing. Circulation (1999) 99:3213–3214.
   Google Scholar
• DESWAL A, BOZKURT B, SETA Y etal.:Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, Etanercept) in patients with advanced heart failure. Circulation (1999) 99:3224–3226.
   Google Scholar
• BOZKURT B, TORRE-AMIONE G, WARREN MS: Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation (2001) 101:1044–1047.
   Google Scholar
• MILLER MD, KRANGEL MS: Biologyand biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines. Grit. Rev. Immurrol (1992) 12:17–46.
   PubMed Web of Science ®Google Scholar
• KUKIELKA GL, SMITH CW, LAROSA GJ et al.: Interleukin-8 gene induction in the myocardium after ischemia and reperfusion in vivo. j Clirr. Invest. (1995) 95:89–103.
   PubMed Web of Science ®Google Scholar
• PANNITTERI G, MARINO B, CAMPA PP, MARTUCCI R, TESTA U, PESCHLE C: Interleukins 6 and 8 as mediators of acute phase response in acute myocardial infarction. Am. J Cardiol (1997) 80:622–625.
   PubMed Web of Science ®Google Scholar
• CALVILLO L, BERTINI R, PORZIO S et al.: Reduction of ischemia-reperfusion injury in the rat in vivo by DF-1681A, an inhibitor of interleukin-8. _J. Am. Coll. Cardiol (2001) 37:374A.
   Web of Science ®Google Scholar
• HEARSE DJ, HUMPHREY SM, CHAIN EB: Abrupt reoxygenation of the anoxic potassium-arrested perfused rat heart: a study of myocardial enzyme release. I Mal. Cell. Cardiol. (1973) 5:395–407.
   PubMed Web of Science ®Google Scholar
• •Pioneer study on the pathogenetic role of oxygen in reperfusion injury.
   Google Scholar
• EDDY LJ, STEWART JR, JONES HP, ENGERSON TD, MCCORD JM, DOWNEY JM: Free radical-producing enzyme, xanthine oxidase, is undetectable in human hearts. Am. I Physiol. (1987) 253:H709–H711.
   PubMed Web of Science ®Google Scholar
• FLAHERTY JT, WEISFELDT ML: Reperfusion injury. Free Radic. Biol. Med. (1988) 5:409–419.
   PubMed Web of Science ®Google Scholar
• JOLLY SR, KANE WJ, BAILIE MB, ABRAMS GD, LUCCHESI BR: Canine myocardial reperfusion injury. Its reduction by the combined administration of superoxide dismutase and catalase. Circ. Res. (1984) 54:277–285.
   Google Scholar
• PRZYKLENK K, KLONER RA: `Reperfusion injury' by oxygen-derived free radicals? Effect of superoxide dismutase plus catalase, given at the time of reperfusion, on myocardial infarct size, contractile function, coronary microvasculature, and regional myocardial blood flow. Circ. Res. (1989) 64:86–96.
   PubMed Web of Science ®Google Scholar
• PRZYKLENK K, KLONER RA: Oxygen radical scavenger agents as adjuvant therapy with tissue plasminogen activator in a canine model of thrombolysis. Cardiovasc. Res. (1993) 27:925–934.
   PubMed Web of Science ®Google Scholar
• WATANABE BI, LIMM W, SUEHIRO A, SUEHIRO G, PREMARATNE S, MCNAMARA JJ: Failure of deferoxamine to reduce myocardial infarct size in a primate model of ischemia-reperfusion injury. I &mg. Res. (1993) 55:537–542.
   Google Scholar
• VANHAECKE J, VAN DE WERF F, RONASZEKI A, FLAMENG W, LESAFFRE E, DE GEEST H: Effect of superoxide dismutase on infarct size and postischemic recovery of myocardial contractility and metabolism in dogs. I Am. Coll. Cardiol. (1991) 18:224–230.
   PubMed Web of Science ®Google Scholar
• FLAHERTY JT, PITT B, GRUBER J etal.: Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. Circulation (1994) 89:1982–1991.
   Google Scholar
• ENGLER R, GILPIN E: Can superoxidedismutase alter myocardial infarct size? Circulation (1989) 79:1137–1142.
   PubMed Web of Science ®Google Scholar
• •Critical evaluation of different experimental studies, addressing the issue of transferability of their results into human research.
   Google Scholar
• BOLLI R: Superoxide dismutase 10 yearslater: a drug in search of a use. I Am. Coll. Cardiol. (1991) 18:231–233.
   PubMed Web of Science ®Google Scholar
• WANG D, YU X, COHEN RA, BRECHER P: Distinct effects of N-acetylcysteine and nitric oxide on angiotensin II-induced epidermal growth factor receptor phosphorilation and intracellular Ca2+ levels. j Biol. Chem. (1999) 275:12223–12230.
   Web of Science ®Google Scholar
• BLACKWELL TS, BLACKWELL TR, HOLDEN EP, CHRISTMAN BW, CHRISTMAN JW: In vivo antioxidant treatment suppresses nuclear factor-icB activation and neutrophilic lung inflammation. I Immurrol. (1996) 157:1630–1637.
   Google Scholar
• KUSHNER I, BRODER ML, KARP D: Control of the acute phase response. Serum C-reactive protein after acute myocardial infarction. j OM. Invest. (1978) 61:235–242.
   Google Scholar
• •Pioneering study proving in vivo in humans an association between MI and inflammation.
   Google Scholar
• CERMAK J, KEY NS, BACH RR, BALLA J; JACOB HS, VERCELLOTTI GM: C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood (1993) 82:513–520.
   PubMed Web of Science ®Google Scholar
• LIUZZO G, ANGIOLILLO DJ, BUFFON A et al.: Enhanced response of blood monocytes to in vitro lipopolysaccharide-challenge in patients with recurrent unstable angina. Circulation (2001) 103:2236–2241.
   PubMed Web of Science ®Google Scholar
• PASCERI V, WILLERSON JT, YEH ETH: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation (2000) 102:2165–2168.
   PubMed Web of Science ®Google Scholar
• GRISELLI M, HERBERT J, HUTCHINSON WL etal.: C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. I Esp. Med. (1999) 190:1733–1739.
   Google Scholar
• •An elegant experimental study that examines the interplay between CRP and complement during ischaemic cardiac injury.
   Google Scholar
• XIA D, SAMOLS D: Transgenic mice expressing rabbit C-reactive protein are resistant to endotoxemia. Proc. Nati Acad. Sci. USA (1997) 94:2575–2580.
   PubMed Web of Science ®Google Scholar
• ZHONG W, ZEN Q, TEBO J, SCHLOTTMANN K, COGGESHALL M, MORTENSEN RF: Effect of human C-reactive protein on chemokine and chemotactic factor-induced neutrophil chemotaxis and signaling. I Immurrol. (1998) 161:2533–2540.
   Google Scholar
• LIUZZO G, BIASUCCI LM, GALLIMORE JR et al: The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N. Engl. J Med. (1994) 331:417–424.
   PubMed Web of Science ®Google Scholar
• •A study which triggered a series of researches in the field of CRP and prognosis in CHD.
   Google Scholar
• RIDKER PM, CUSHMAN M, STAMPFER MJ, TRACY RE HENNEKENS CH. Inflammation, asprin, and risks of cardiovascular disease in apparently health men. N Engl. I Med. (1997) 336:973–979.
   Google Scholar
• ••First study to document the associationbetween the beneficial effect of aspirin in cardiovascular prevention and its anti-inflammatory action.
   Google Scholar
• RIDKER PM, BURING JE, SHIH J, MATIAS M, HENNEKENS CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently health women. Circulation (1998) 98:731–733.
   Google Scholar
• BOTTAZZI B, VOURET-CRAVIARI V, BASTONE A et al.: Multimer formation and ligand recognition by the long pentraxin PTX3: similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. I Biol. Chem. (1997) 272:32817–32823.
   Web of Science ®Google Scholar
• INTRONA M, VIDAL ALLES V, CASTELLANO M etal.: Cloning of mouse PTX3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood (1996) 87:1862–1872.
   Google Scholar
• •First demonstration of the existence of a new pentraxin, and its characterisation.
   Google Scholar
• PERI G, INTRONA M, CORRADI D et al.: PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction. Circulation (2000) 102:636–641.
   PubMed Web of Science ®Google Scholar
• DANESH J, COLLINS R, PETO R: Chronic infections and coronary heart disease: is there a link? Lancet (1997) 350:430–436.
   PubMed Web of Science ®Google Scholar
• •Critical and exhaustive overview by the most authoritative group in clinical trial methodology.
   Google Scholar
• GURFINKEL E, BOZOVICH G, BECK E, TESTA E, LIVELLARA B, MAUTNER B: Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS study. Eur. Heart J. (1999):20:121–127.
   PubMed Web of Science ®Google Scholar
• MUHLESTEIN JB, ANDERSON JL, CARLQUIST JF et al.: Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation (2000) 102:1755–1760.
   PubMed Web of Science ®Google Scholar
• JACKSON LA: Description and status of the azithromycin and coronary events study (ACES). J. Infect. Dis. (2000) 181:S579–S581.
   PubMed Web of Science ®Google Scholar
• DUNNE MW: Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (weekly intervention with zithromax lazithromycinl for atherosclerosis and its related disorders) trial. ..J. Infect. Dis. (2000) 181:S572–S578.
   PubMed Web of Science ®Google Scholar
• MARON DJ, FAZIO S, MACRAE FL: Current perspectives on statins. Circulation (2000) 101:207–213.
   PubMed Web of Science ®Google Scholar
• PALINSKI W: New evidence for beneficial effects of statins unrelated to lipid lowering. Atherioscler. Thromb. Vasc. Biol. (2001) 21:3–5.
   PubMed Web of Science ®Google Scholar
• ORTEGO M, BUSTOS C, HERNANDEZ-PRESA MA, TUNON J, DIAZ C, HERNANDEZ G, EGIDO J. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis (1999) 147:253–261.
   Google Scholar
• ROMANO M, DIOMEDE L, SIRONI M et al: Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab. Invest. (2000) 80:1095-1100. so. INOUE I, GOTO S, MIZOTANI K etal.: Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for interleukin-1p, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated repector a (PPARa) in primary endothelial cells. Life Sci. (2000) 67:863–876.
   Google Scholar
• KOTHE H, DALHOFF K, RUPP J et al.: Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydi a prieumorriae. Circulation (2000) 101:1760–1763.
   PubMed Web of Science ®Google Scholar
• •Statins can reduce inflammation of cells infected with C. pneumoniae, that promotes plaque inflammation
   Google Scholar
• KEIDAR S, AVIRAM M, MAOR I, OIKNINE J, BROOK JG: Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: in vitro and in vivo studies. Br. J. Clin. Pharmacol (1994) 38:513–519.
   PubMed Web of Science ®Google Scholar
• AIKAWA M, RABKIN E, OKADA Y et al.: Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation (1998) 97:2433–2444.
   PubMed Web of Science ®Google Scholar
• BELLOSTA S, VIA D, CANAVESI M et al.: HMG-CoA reductase inhibitors reduce MIV1P-9 secretion by macrophages. Arteriosler. Thromb. Vasc. Biol. (1998) 18:1671–1678.
   PubMed Web of Science ®Google Scholar
• SHIOMI M, ITO T, TSUKADA T etal.:Reduction of serum cholesterol levels alters lesional composition of atheroslecrotic plaques: effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Arteriosler. Thromb. Vasc. Biol. (1995) 15:1938–1944.
   Google Scholar
• WILLIAMS JK, SUKHOVA GK, HERRINGTON DM, LIBBY P: Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J. Am. Coll Cardiol (1998) 31:684–691.
   PubMed Web of Science ®Google Scholar
• JIALAL I, STEIN D, BALIS D, GRUNDY SM, ADAMS-HUET B, DEVARAJ S: Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation (2001) 103:1933–1935.
   PubMed Web of Science ®Google Scholar
• DI GARBO V, BONO M, DI RAIMONDO D et al: Non lipid, dose-dependent effects of pravastatin treatment on hemostatic system and inflammatory response. Eur. j OM. Pharmacol (2000) 56:277–284.
   PubMed Web of Science ®Google Scholar
• SPARROW CP, BURTON CA, HERNANDEZ M et al.: Simavastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arteriosler. Thromb. Vase. Biol. (2001) 21:6–12.
   PubMedGoogle Scholar
• LEFER AM, CAMPBELL B, SHIN YK,SCALIA R, HAYWARD R, LEFER DJ. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation (1999) 100:178–184.
   Google Scholar
• •First experimental evidence on cardioprotective effects of statins not mediated by cholesterol reduction.
   Google Scholar
• DECHEND R, FIEBELER A, PARK JK et al.: Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Circulation (2000) 104:576–581.
   Web of Science ®Google Scholar
• KOBASHIGAWA JA, KATZNELSON S, LAKS H et al: Effect of pravastatin on outcomes after cardiac transplantation. N Engl. J. Med. (1995) 333:621–627.
   PubMed Web of Science ®Google Scholar
• HOLM T, ANDREASSEN AK, UELAND T et al: Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. Am. J. Cardiol (2001) 87:815–818.
   PubMed Web of Science ®Google Scholar
• KWAK B, MULHAUPT F, MYIT S, MACH F: Statins as a newly recognized type of immunosuppressor. Nature Med. (2000) 6:1399–1402.
   PubMed Web of Science ®Google Scholar
• •This study opens new perspectives on the role of statins as immunomodulators.
   Google Scholar
• RIDKER PM, RIFAI N,PFEFFER MA et al.: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation (1998) 98:839–844.
   Google Scholar
• RIDKER PM, RIFAI N, PFEFFER MA, SACKS F, BRAUNWALD E, FOR THE CHOLESTEROL AND RECURRENT EVENTS (CARE) INVESTIGATORS. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation (1999) 100:230–235.
   Google Scholar
• RIDKER PM, RIFAI N, CLEARFIELD M et al.: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl. J. Med. (2001) 344:1959–1965.
   PubMed Web of Science ®Google Scholar
• •First study to suggest a role of CRP for the identification of patients to be treated chronically for prevention of cardiovascular events.
   Google Scholar
• ALBERT MA, DANIELSON E, RIFAI N, RIDKER PM, for the PRINCE Investigators: Effect of statin therapy on C-reactive protein levels. The pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA (2001) 286:64–70.
   Google Scholar
• •First prospective study in general practice to show that statins decrease CRP levels.
   Google Scholar
• FITCH JC, ROLLINS S, MATIS L et al: Pharmacology and biological efficacy of a recombinant, humanized, single-chainantibody C5 complement inhibitor I patients undergoing coronary artery bpass graft surgery with cardiopulmonary bypass. Circulation (1999) 100:2499–2506.
   PubMed Web of Science ®Google Scholar
• AUKRUST P, GULLESTAD L, LAPPERGARD KT et al. Complement activation in patients with congestive heart failure. Effect of high-dose intravenous immunoglobulin treatment. Circulation (2001) 104:1494–1500.
   Google Scholar
• KITAKAZE M, HORI M: Adenosine therapy: new approach to chronic heart failure. Expert Opin. Investig. Drugs (2000) 9:2519–2535.
   PubMed Web of Science ®Google Scholar
• ELY SW, BERNE RM: protective effects of adenosine in myocardial ischemia. Circulation (1992) 85:893–904.
   PubMed Web of Science ®Google Scholar
• WAGNER DR, COMBES A, MCTIERNAN C, SANDERS VJ, LEMSTER B, FELDMAN AM: Adenosine inhibits lipopolysaccharide-induced cardiac expression of tumor necrosis factor-a. Circ. Res. (1998) 82:47–56.
   PubMed Web of Science ®Google Scholar
• CRONSTEIN BN, KRAMER SB, WEISSMANN G, HIRSCHHORN R: Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. Exp. Med. (1983) 158:1160–1177.
   PubMed Web of Science ®Google Scholar
• AUCHAMPACH JA, GROSS GJ. Adenosine A1 receptors, KAip channels and ischemic preconditionning in dogs. Am. J. Physiol. (1993) 264:H1327–H1336.
   PubMed Web of Science ®Google Scholar
• ZHAO ZQ, SATO H, WILLIAMS MW, FERNANDEZ AZ, VINTEN-JOHANSEN J: Adenosine A2-receptor activation inhibits neutrophil-mediated injury to coronary endothelium. Am. J. Physic] (1996) 271:H1456–H1464.
   Web of Science ®Google Scholar
• JORDAN JE, ZHAO ZQ, VINTEN-JOHANSEN J: Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J. Pharmacol. Exp. Ther. (1997) 280:301–309.
   PubMed Web of Science ®Google Scholar
• JORDAN JE, THOURANI VH, AUCHAMPACH JA et al.: A3 adenosine receptor activation attenuates neutrophil function and neutrophil-mediated reperfusion injury. Am. J. Physic] (1999) 277: H1895–H1905.
   Web of Science ®Google Scholar
• OLAFSSON B, FORMAN MB, PUETT DW et al.: Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and no-reflow phenomenon. Circulation (1987) 76:1135–1145.
   PubMed Web of Science ®Google Scholar
• BABBITT DG, VIRMANI R, VILDIBILL HD JR NORTON ED, FORMAN MB. Intracoronary adenosine administration during reperfusion following 3 hours of ischemia: effects on infarct size, ventricular function, and regional myocardial blood flow. Am. Heart" (1990) 120:808–818.
   Google Scholar
• ZHAO ZQ, BUDDE JM, MORRIS C et al.: Adenosine attenuates reperfusion-induced apoptotic cell death by modulating expression of Bc1-2 and Box proteins. J. Malec. Cell. Cardiol. (2001) 33:57–68.
   PubMed Web of Science ®Google Scholar
• BOLLI R: The late phase of preconditioning. Circ. Res. (2000) 87:972–983.
   PubMed Web of Science ®Google Scholar
• MUBAGWA K, FLAMENG W: Adenosine, adenosine receptors and myocardial protection: an updated overview. Cardiovasc. Res. (2001) 52:25–39.
   PubMed Web of Science ®Google Scholar
• HATA K, WHITTAKER P, KLONER RA, PRZYKLENK K: Brief antecedent ischemia attenuates platelet-mediated thrombosis in damaged and stenotic canine coronary arteries. Role of adenosine. Circulation (1998) 97:692–702.
   PubMed Web of Science ®Google Scholar
• ANDREOTTI E PASCERI V, HACKETT DR et al.: Preinfarction angina as a predictor of more rapid coronary thrombolysis in patients with acute myocardial infarction. N Engl. J. Med. (1996) 334:7–12.
   PubMed Web of Science ®Google Scholar
• MAHAFFEY KW, PUMA JA, BARBAGELATA NA etal.: Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction Study of Adensoine (AMISTAD). J. Am. Co]] Cardiol (1999) 34:1711–1720.
   Google Scholar
• ••This Phase II controlled clinical trialdemonstrates a reduction of infarct size by adenosine: possibly the only one evidence of therapeutic success with an agent aimed at reducing reperfusion injury, but not only.
   Google Scholar
• MARZILLI M, ORSINI E, MARRACCINI E TESTA R: Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation (2000) 101:2154–2159.
   PubMed Web of Science ®Google Scholar
• GRUBER HE, HOFFER ME, MCALLISTER DR et al.: Increased adenosine concentration in blood from ischemic myocardium by AICA riboside: effects on flow, granulocytes, and injury. Circulation (1989) 80:1400–1411.
   PubMed Web of Science ®Google Scholar
• KINGSMA JG JR, SIMARD D, ROULEAU JL: Timely adminsitration of AICA riboside reduces reperfusion injury in rabbits. Cardiovasc. Res. (1994) 28:1003–1007.
   PubMed Web of Science ®Google Scholar
• MENTZER RIVI JR, ELY SW, LASLEY RD, BERNE RM: The acute effects of AICAR on purine nucleotide metabolism and postischemic cardiac function. J. Thoracic Cardiovasc. Surg. (1988) 95:286–293.
   PubMed Web of Science ®Google Scholar
• DORTON M, ROULEAU J, KINGMA JG JR: Failure of AICA riboside to limit infarct size during acute myocardial infarction in rabbits. J. Cardiovasc. Pharmacol. (1992) 19:69–77.
   PubMed Web of Science ®Google Scholar
• MANGANO DT, FOR THE MULTICENTER STUDY OF PERIOPERATIVE ISCHEMIA (MCSPI) RESEARCH GROUP: Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials. JAMA (1997) 277:325–332.
   Google Scholar
• •Acadesine (AICA riboside, a purine nucleoside) reduces the incidence of cardiovascular complications in patients undergoing CABG surgery.
   Google Scholar
• BELARDINELLI L, LINDEN J, BERNE RM: The cardiac effects of adenosine. Frog. Cardiovasc. Dis. (1989) 32:73–97.
   PubMed Web of Science ®Google Scholar
• MARTIN BJ, LASLEY RD, MENTZER RM JR: Infarct size reduction with the nucleoside transport inhibitor R-75231 in swine. Am. J. Physic] (1997) 272: H1857–H1865.
   Web of Science ®Google Scholar
• MANN DL, SPINALE FG: Activation of matrix metalloproteinases in the failing human heart. Breaking the tie that binds. Circulation (1998) 98:1699–1702.
   PubMed Web of Science ®Google Scholar
• COKER ML, JOLLY JR, JOFFS C et al.: Matrix metalloproteinase expression and activity in isloated myocytes after neurohormonal stimulation. kn. J. Physic] (2001) 281:H543–H551.
   PubMed Web of Science ®Google Scholar
• RAJAGOPALAN S, MENG XI RAMASAMY S, HARRISON DG, GALLS ZS: Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. J. OM. Invest. (1996) 98:2572–2579.
   PubMed Web of Science ®Google Scholar
• FERRY G, LONGCHAMPT M, PENNEL L et al.: Activation of MMP-9 by neutrophil elastase in an in vivo model of acute lung injury. FEBS Lett. (1997) 402:111–115.
   PubMed Web of Science ®Google Scholar
• YASMIN W, STRYNADKA KD, SCHULZ R: Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts. Cardiovasc. Res. (1997) 33:422–432.
   PubMed Web of Science ®Google Scholar
• FREARS ER, ZHANG Z, BLAKE DR, O'CONNELL JP, WINYARD PJ: Inactivation of tissue inhibitor of metalloproteinase-1 by peroxynitrite. FEBS Lett. (1996) 381:21–24.
   PubMed Web of Science ®Google Scholar
• BAGHELAI K, MARKTANNER R, DATTILO JB etal.: Decreased expression of tissue inhibitor of metalloproteinase-1 in stunned myocardium. j Surg. Res. (1998) 77:35–39.
   Google Scholar
• CHEUNG PY, SAWICKI G, WOZNIAK M et al: Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation (2000) 101: 1833-1839.
   Google Scholar
• LINDSEY M, WEDIN K, BROWN MD et al.: Matrix-dependent mechanism of neutrophil mediated release and activation of matrix metalloproteinase-9 in myocardial ischemiaireperfusion. Circulation (2001) 103:2181–2187.
   PubMed Web of Science ®Google Scholar
• VAN DEN STEEN PE, PROOST P, WUYTS A, VAN DAMME J, OPDENAKKER G: Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4 and GRO-alpha and leaves RANTES and MCP-2 intact. Blood (2000) 96:2673–2681.
   PubMed Web of Science ®Google Scholar
• ENTMAN ML, NOSSULI TO, LAKSHMINARAYANAN V, MICHAEL LH: For want of a few good shams. Am. Physiol (2000) 278:H1017–H1018.
   PubMed Web of Science ®Google Scholar
• •This paper raises important issues on the adequacy of experimental models in cardiac I/R injury.
   Google Scholar